HOME >> BIOLOGY >> NEWS
Pharmaceutical 'smart bomb' targets cancer cells

NEW BRUNSWICK/PISCATAWAY, N.J. Rutgers pharmaceutical chemist Longqin Hu and his colleagues have developed a new series of compounds for drugs that have the potential to attack cancer like a high-tech "smart bomb." This high-powered combination of a novel cell-killing agent and a precision targeting technology proved to be as much as 100 times more potent than a comparable drug currently in clinical trials.

"We are testing this combination and it looks like a winner," said Hu, an assistant professor at the Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey.

The delivery of the compound is accomplished with a prodrug an inert chemical derivative of a drug that can be activated once it reaches its destination inside a patient's body. Prodrugs can transport highly potent medicines such as Hu's cytotoxins (cell-killers), without impacting other body tissues along the way. Hu's research employs a new and improved prodrug package developed by collaborators in England.

This dramatic step in the march toward a cancer cure will be featured twice during the 226th American Chemical Society (ACS) national meeting in New York. Hu is presenting a paper on Monday, Sept. 8 at 3:45 p.m. in the Javits Convention Center, room 1E02. In addition, Hu and his colleagues are exhibiting at a poster session on Wednesday, Sept. 10 in the Hilton New York, Americas Hall 1 from 6 p.m. to 8 p.m.

Traditional anticancer drugs use accelerated cell growth as their trigger, which can produce collateral damage in rapidly replicating normal cells. "That is how you wind up with the negative side effects you see in chemotherapy patients, such as hair loss, nausea and reduced immunities," said Hu.

Instead of hitting all cells that grow fast, the newly reformulated prodrugs use a protein or enzyme as the activating trigger, guaranteeing a direct hit on cancerous cells. Nitroreductase an enzyme not normally found in the body, not
'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 Ext. 652
Rutgers, the State University of New Jersey
31-Dec-2000


Page: 1 2

Related biology news :

1. Warren Pharmaceuticals publishes results of preclinical evaluation
2. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
3. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
4. Pharmaceutical and personal care products: What happens when they enter the environment - an emerging concern
5. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
6. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
7. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
8. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
9. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
10. Micro-Plants Yield Pharmaceutical New Wave
11. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pharmaceutical smart bomb targets cancer cells

(Date:4/22/2014)... Scientists at the University of Massachusetts Amherst and the ... week report that they have discovered a new genus ... the Negro River in the Amazonia State of Brazil. ... Adlia Nogueira and Jos Antnio Alves-Gomes of INPA, describe ... the journal Proceedings of the Natural Sciences of ...
(Date:4/22/2014)... at the University of Kentucky has discovered new methods ... , The research, led by Peixuan Guo, professor ... the UK College of Pharmacy and Markey Cancer Center, ... Boiling-Resistant Anionic Polymer Material To Build Robust Structures with ... and Daniel L. Jasinski. , The article, which will ...
(Date:4/22/2014)... trip to Asia to coordinate with allies and ... at the Office of Naval Research (ONR) emphasized ... as an example of strong and growing ties ... the region. , The APTEP program, centered in ... the development of alternative energy technologies. It takes ...
Breaking Biology News(10 mins):New electric fish genus and species discovered in Brazil's Rio Negro 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
Cached News: